| scholarly article | Q13442814 |
| P2093 | author name string | David E Kleiner | |
| P2860 | cites work | Ecstasy induced acute hepatic failure. Case reports | Q85483659 |
| Acute liver failure associated with Garcinia cambogia use | Q86839806 | ||
| Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance | Q87024749 | ||
| Anakinra-Induced Acute Liver Failure in an Adolescent Patient with Still's Disease | Q87046526 | ||
| A Case of Hepatotoxicity Related to Kombucha Tea Consumption | Q95552367 | ||
| Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases | Q26864098 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide | Q30447260 | ||
| Hepatic failure during anabolic steroid therapy | Q33403937 | ||
| Drug-induced liver injury with autoimmune features complicated with hemophagocytic syndrome | Q33431503 | ||
| Hepatomegaly following short-term high-dose steroid therapy. | Q34196195 | ||
| Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period | Q34440712 | ||
| Dietary supplement use in the United States, 2003-2006 | Q34493137 | ||
| Atypical onset of bicalutamide-induced liver injury | Q34522957 | ||
| Anabolic androgenic steroid-induced hepatotoxicity. | Q34532752 | ||
| Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 | Q34567635 | ||
| Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. | Q34880762 | ||
| Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network | Q34943114 | ||
| The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. | Q35341829 | ||
| Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study | Q35656015 | ||
| Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases | Q35783976 | ||
| Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis | Q35885041 | ||
| Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. | Q36085618 | ||
| Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report | Q36232337 | ||
| Temozolomide-induced biliary ductopenia: a case report | Q36550425 | ||
| Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury | Q36668300 | ||
| Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop | Q36740188 | ||
| Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States | Q36844723 | ||
| Drug-induced liver injury caused by iodine-131 | Q37097608 | ||
| Khat chewing and cirrhosis in Somaliland: Case series | Q37191957 | ||
| Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma | Q37220158 | ||
| Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations | Q37624916 | ||
| Hepatic Sinusoidal Obstruction Syndrome Induced by Non-transplant Chemotherapy for Non-Hodgkin Lymphoma | Q37719073 | ||
| Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver | Q37818983 | ||
| Acute hepatitis associated with clopidogrel: a case report and review of the literature | Q38121005 | ||
| Experience with OxyELITE pro and acute liver injury in active duty service members | Q38219315 | ||
| Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature | Q38351883 | ||
| Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature. | Q38393472 | ||
| Febuxostat-induced acute liver injury. | Q38603701 | ||
| Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports | Q38620305 | ||
| Natalizumab-induced hepatic injury: A case report and review of literature | Q38641614 | ||
| Methylprednisolone-induced liver injury: Case report and literature review | Q38671657 | ||
| Bupivacaine drug-induced liver injury: a case series and brief review of the literature | Q38862480 | ||
| Khat-induced liver injuries: A report of two cases. | Q39200130 | ||
| Incidence of drug-induced hepatic injuries: a French population-based study | Q39609276 | ||
| Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury | Q39677764 | ||
| Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions | Q40076404 | ||
| Hepatic Lesions Caused by Anabolic and Contraceptive Steroids | Q40130806 | ||
| An unusual cause of febrile hepatitis | Q40149987 | ||
| An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis | Q40373033 | ||
| Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements | Q40422372 | ||
| Recurrent Acute Liver Failure Because of Acute Hepatitis Induced by Organic Solvents: A Case Report | Q40997120 | ||
| Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. | Q41022298 | ||
| New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease | Q41256627 | ||
| Acute Cholestatic Liver Injury From Hydralazine Intake | Q41467486 | ||
| Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases | Q41700706 | ||
| Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series | Q41881118 | ||
| A case of levocetirizine-induced liver injury | Q42327996 | ||
| Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. | Q43050091 | ||
| Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. | Q46542938 | ||
| Paracetamol-induced Stevens Johnson syndrome and cholestatic hepatitis | Q46961246 | ||
| Sertraline-Associated Cholestasis and Ductopenia Consistent with Vanishing Bile Duct Syndrome | Q48069955 | ||
| Agomelatine-induced liver injury in a patient with choledocholithiasis | Q48187972 | ||
| Acute temozolomide induced liver injury : Mixed type hepatocellular and cholestatic toxicity. | Q48590916 | ||
| Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. | Q49022529 | ||
| Incomplete septal cirrhosis after high-dose methylprednisolone therapy and regression of liver injury. | Q50182833 | ||
| Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? | Q50456035 | ||
| Nimesulide-induced fatal acute liver failure in an elderly woman with metastatic biliary adenocarcinoma. A case report. | Q50459666 | ||
| Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. | Q50628941 | ||
| Risk of drug-induced liver injury from tumor necrosis factor antagonists. | Q50643941 | ||
| Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? | Q50921771 | ||
| Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. | Q51206003 | ||
| Autoimmune hepatitis following drug-induced liver injury in an elderly patient. | Q53102848 | ||
| A Case Report of Supplement-Induced Hepatitis in an Active Duty Service Member. | Q53446838 | ||
| Freshwater clam extract supplement-induced acute cholestasis. | Q53458463 | ||
| Cholestatic liver injury secondary to artemisinin. | Q53504746 | ||
| Oral contraceptive-induced hepatic sinusoidal dilatation. | Q53584147 | ||
| Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. | Q54658565 | ||
| Hepatoportal sclerosis related to the use of herbals and nutritional supplements. Causality or coincidence? | Q57132932 | ||
| A case of nodular regenerative hyperplasia of the liver combined with toxic hepatitis | Q57221832 | ||
| The effects of phenobarbital and diphenylhydantoin on liver function and morphology | Q72424788 | ||
| DRUG-INDUCED LIVER DISEASE: A PENALTY FOR PROGRESS | Q78504740 | ||
| Glycogen pseudoground glass change in hepatocytes | Q80165758 | ||
| Ground-glass, polyglucosan-like hepatocellular inclusions: A "new" diagnostic entity | Q80212350 | ||
| Cholestasis secondary to anabolic steroid use in young men | Q83389430 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 297-311 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Surgical pathology clinics | Q27723038 |
| P1476 | title | Recent Advances in the Histopathology of Drug-Induced Liver Injury | |
| P478 | volume | 11 |
| Q96131824 | Biopsy pathology and immunohistochemistry of a case of immune-mediated drug-induced liver injury with Atabecestat | cites work | P2860 |
Search more.